Research means finding answers to questions.​

The questions that we concern ourselves with arise from our everyday work in our practice. The search for answers aims to constantly continue the development of the active-specific immunotherapy against cancer and to make the results of our research generally accessible.

 

The purpose of the IOZK Foundation is to develop the scientific basis of immuno-oncological research and its translation into practice. The measures aim to promote the research of therapy options against cancer and the swift implementation of their results into patient care in accordance with regulatory guidelines. 

 

Retrospective 2020

 

The year 2020 was, as far as research activities are concerned, quite successful. Colleagues from our team were able to introduce the knowledge on immunologic cancer therapy produced at the IOZK to the international scientific exchange. Furthermore, our basic research on cell-based therapies continues to develop.

 

This same year, many students received support in experiments, which they carried out in exchange with our experts at the IOZK. The future medics, biologists or biotechnologists researched for their bachelor, master or doctoral theses and obtained very interesting results.

HOME

Two T cells on a cancer cell, scanning electron microscopy, Steve Gschmeissner/Science Photo.

Research means finding answers to questions.​

In the foundation's magazine IOZK Consilium and our technical brochure, you will receive further information on the context and the scientific background of our immunotherapy.​

The questions that we concern ourselves with arise from our everyday work in our practice. The search for answers aims to constantly continue the development of the active-specific immunotherapy against cancer and the swift implementation of their results into patient care

 

The purpose of the IOZK Foundation is to develop the scientific basis of immuno-oncological research and its translation into practice. The measures aim to promote the research of therapy options against cancer to enable a swift translation of results into patient care in accordance with regulatory guidelines.

 

Retrospective 2020

 

The year 2020 was, as far as research activities are concerned, quite successful. Colleagues from our team were able to introduce the knowledge on immunologic cancer therapy produced at the IOZK to the international scientific exchange. Furthermore, our basic research on cell-based therapies continues to develop.

 

This same year, many students received support in experiments, which they carried out in exchange with our experts at the IOZK. The future medics, biologists or biotechnologists researched for their bachelor, master or doctoral theses and obtained very interesting results.

Two T cells on a cancer cell, scanning electron microscopy, Steve Gschmeissner/Science Photo​

GERMAN MEDICAL AWARD, NovEMBER 17, 2020

 

 

Dr. Wilfried Stücker – in representation of the IOZK – received a distinction for outstanding performance.

 

The prestigious award is granted to “trend setters of medicine“ who have made themselves particularly worthy by a medical innovation that improves patient care. In the category for innovation in oncology, the IOZK was granted, in the person of Dr. Stücker, the second place on November 17th, 2020. It is a public distinction for the work of many years in the area of immuno-oncology and for the innovative therapy approach at the same time.

 

“In his therapy, Dr. Stücker tries not to introduce a substance from without, but to strengthen and activate the body‘s own defences so that they can act against the tumour tissue. Since it is the body‘s own tissue, the defence system does not recognize or fight it. The trick is to make a kind of vaccine with a virus. The virus moves into the tumour tissue, so the body recognizes it as foreign and the immune system begins to fight the tumour – a very elegant method“, commented Prof. Dr. med Matthias Keidel from Bad Neustadt in his laudation. Dr. med Christian Weißenberger from Freiburg added: “The idea is to use viruses to improve the body‘s own defences, so that these will find all tumour cells and continue to do so life-long.“

 

The German Medical Award exists as a specialized prize for medicine of the future since 2015, in collaboration with the state capital Düsseldorf, under the auspice of Karl-Josef Laumann, minister of labour, health and social affairs of the federal state of North Rhine-Westphalia and supported by MEDICA Düsseldorf. The award is the leading and only distinction for medicine in ­Germany, Austria and Switzerland.

If you have further questions, please contact us:

 

tel +49 (0)221 - 420 399 127

e-mail: stiftung@iozk.de

GERMAN MEDICAL AWARD, NovEMBER 17, 2020

 

In the category for innovation in oncology, the IOZK was granted, in the person of Dr. Stücker, the second place. It is a public distinction for the work of many years in the area of immuno-oncology and for the innovative therapy approach at the same time.

 

“In his therapy, Dr. Stücker tries not to introduce a substance from without, but to strengthen and activate the body‘s own defences so that they can act against the tumour tissue. Since it is the body‘s own tissue, the defence system does not recognize or fight it. The trick is to make a kind of vaccine with a virus. The virus moves into the tumour tissue, so the body recognizes it as foreign and the immune system begins to fight the tumour – a very elegant method“, commented Prof. Dr. med Matthias Keidel from Bad Neustadt in his laudation. Dr. med Christian Weißenberger from Freiburg added: “The idea is to use viruses to improve the body‘s own defences, so that these will find all tumour cells and continue to do so life-long.“

 

The prestigious german award is for “trend setters" of medicine who have made themselves particularly worthy by a medical innovation that improves patient care.

In our magazine IOZK Consilium and our brochure you will find more information about the scientific background of our cancer therapy.​

Further information

de   eng